Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma, a Pilot Study

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are [18F]DPA-714 and 18F-GE180. We hypothesize that [18F]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Center Eugene Marquis

Criteria

Inclusion Criteria:

• Age greater than or equal to 18 years

• Suspicion of an operable diffuse glioma

• Written informed consent (signed)

• Affiliated or beneficiary of a social security plan

Exclusion Criteria:

• Suspicion of grade I glioma

• Surgical urgency (less than 8 days between the suspected diagnosis and surgery)

• Pregnant or breastfeeding woman

• Persons deprived of liberty or under guardianship

• Impossibility to undergo the medical follow-up of the trial for geographical, social or psychological reasons